^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6123

    i
    Other names: RG6123, RO7172508, RG 6123, RO 7172508
    Associations

    News

    Trials
    Company:
    Roche
    Drug class:
    CEA inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; Completed --> Terminated; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
    Trial termination • Clinical
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    over4years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1; N=26; Completed; Sponsor: Hoffmann-La Roche; Terminated --> Completed
    Trial completion • Clinical
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    over4years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=26, Completed, Hoffmann-La Roche | Terminated --> Completed
    Clinical • Trial completion
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    almost5years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1; N=26; Terminated; Sponsor: Hoffmann-La Roche; N=150 --> 26; Trial completion date: Dec 2020 --> Jul 2019; Recruiting --> Terminated; Trial primary completion date: Dec 2020 --> Jul 2019
    Trial completion date • Trial primary completion date • Enrollment change • Trial termination • Clinical
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    almost5years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=26, Terminated, Hoffmann-La Roche | N=150 --> 26 | Trial completion date: Dec 2020 --> Jul 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2020 --> Jul 2019; Study terminated due to change in benefit-risk ratio, driven by high incidence GI toxicity in absence of clinically significant anti-tumor efficacy.
    Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    almost5years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Jun 2021 --> Dec 2020
    Clinical • Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123
    5years
    A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors (clinicaltrials.gov)
    P1, N=150, Recruiting, Hoffmann-La Roche | Trial completion date: Apr 2020 --> Jun 2021 | Trial primary completion date: Oct 2019 --> Dec 2020
    Clinical • Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6123